pharmaphorum

SEPTEMBER 21, 2020

At this year’s European Society for Medical Oncology (ESMO) conference, Amgen announced updated data from the full phase 1 cohort of the CodeBreak 100 study. Data simultaneously published in the New England Journal of Medicine from 59 patients with non-small cell lung cancer (NSCLC) was highlighted during an oral presentation at ESMO.

58

58

European Pharmaceutical Review

SEPTEMBER 26, 2022

At the 2022 European Society for Medical Oncology Congress (ESMO) conference, promising results from a Phase I trial, suggesting that a novel genetically modified (GM) herpes virus eradicated or reduced advanced cancers, were presented.

Immunization 90

Immunization 90

pharmaphorum

OCTOBER 25, 2021

months to 23 months, according to data reported at this year’s ESMO cancer conference. The combination cut the risk of death by 27% compared to chemo alone in these patients, and helped patients to extend their lives by around 6.9 It also reduced the chances of disease progression or death by 35%.

Chemotherapy 87

Chemotherapy FDA Labelling 87

pharmaphorum

SEPTEMBER 15, 2020

Details of the trial, which showed Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously treated patients with advanced mTNBC, are due to be announced at the European Society of Medical Oncology (ESMO) conference this week.

FDA 82

FDA 82

pharmaphorum

JANUARY 20, 2021

The deal came off the back of phase 1 results announced at the 2018 European Society for Medical Oncology (ESMO) conference. There was another €500 million ($605m) tied to the lung cancer development programme, plus up to €2.9bn ($3.5bn) in development and commercial milestones.

52

52

pharmaphorum

APRIL 25, 2022

Questions have however been raised about the design of Sanofi’s study, particularly that it did not zero in on patients with a specific mutation – called ESR1 – that confers resistance to standard hormonal therapies for breast cancer.

68

68

pharmaphorum

OCTOBER 26, 2021

Preliminary results with the ADC in NSCLC were reported at this year’s ESMO cancer conference and revealed objective response rates of 21% to 25% when used as a monotherapy in heavily pre-treated patents.

Chemotherapy 58

Chemotherapy 58

pharmaphorum

SEPTEMBER 21, 2021

At the ESMO congress – which ends today – results of the innovaTV 205 trial of Tivdak alongside carboplatin in previously untreated advanced cervical cancer revealed a 55% objective response rate (ORR). Seagen and Genmab are hosting a conference call later today to discuss further details of the new product.

FDA 52

FDA Chemotherapy Labelling 52

pharmaphorum

DECEMBER 23, 2020

The American Society of Clinical Oncology (ASCO) annual conference was one of the highlights of the year in cancer research and the fact it was held virtually did not distract from some stunning clinical lung cancer trial results presented by AstraZeneca.

FDA 96

FDA Chemotherapy Compounding Vaccines 96

Pharmaceutical Technology

SEPTEMBER 14, 2022

This week, at the European Society of Medical Oncology (ESMO) Congress 2022 researchers presented encouraging updates on immunotherapies in the field of cervical cancer. months, following an ESMO 2019 presentation on data from the same study. Preventive strategies were a major focus at the ESMO 2022 congress. months and 5.8

Vaccines 59

Vaccines Chemotherapy Dosage FDA 59

PharmaShots

JUNE 1, 2023

We presented our first results this year at ESMO and ESMO-IO. Safety and clinical activity of the product were presented at ESMO 2022. We reported at ESMO-IO the analysis of immune response of the first 3 cohorts of patients. Smriti: How has the presentation at ESMO-IO proved to be an important milestone for the company?

Immunization 40

Immunization Vaccines Health and Personal Care Stores Labelling 40

pharmaphorum

FEBRUARY 11, 2021

Results announced at the European Society for Medical Oncology (ESMO) conference in September showed a 24% confirmed objective response rate (ORR) by independent central review with a median duration of response (DOR) of 8.3

FDA 105

FDA Chemotherapy 105